Back to search

Article

Eighteen-Month Real-World Outcomes of Intravitreal Aflibercept 8 mg in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A UK Single- Centre Experience

2026-06-05

Abstract excerpt

<title>Abstract</title> <p> <bold>Purpose</bold> Intravitreal aflibercept 8 mg was developed to extend treatment intervals and reduce injection burden in neovascular age-related macular degeneration (nAMD). We evaluated visual, anatomical, and durability outcomes over 18 months in routine clinical practice. <bold>Methods</bold> This retrospective observational study included 102 eyes of 95 treatment-naïve nAM...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
9639198f-6b75-5228-8d84-0e5dc2b22340
DOI
10.21203/rs.3.rs-9784004/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Eighteen-Month Real-World Outcomes of Intravitreal Aflibercept 8 mg in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A UK Single- Centre ExperienceDOI 10.21203/rs.3.rs-9784004/v1
Short-Term Efficacy of Aflibercept 8 mg in Refractory Neovascular Age-Related Macular Degeneration: A Real-World Retrospective Case Series from TaiwanSemantic proximity
Factors associated with achieving various visual acuity outcomes during loading doses of aflibercept 2mg for treatment naïve exudative age-related macular degeneration: PRECISE Study Report 7Semantic proximity
Sequential switch from first-line anti-VEGF therapy to faricimab and subsequent aflibercept 8mg in treatment-resistant neovascular AMDSemantic proximity
The Moorfields AMD Database Report 2 - Fellow Eye Involvement with Neovascular Age-related Macular DegenerationSemantic proximity
Clinical care and therapeutic practice of patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) and effectiveness of faricimab in treatment-naive patients in Germany - ZEUS research projectSemantic proximity
Dual pathway inhibition with faricimab for previously treated neovascular age-related macular degeneration and diabetic macular oedema: Guidance from a UK panel of retina specialistsSemantic proximity
Result of Intravitreal Aflibercept Injection for Myopic Choroidal NeovascularizationSemantic proximity
Sterile endophthalmitis following same-day intravitreal aflibercept 8 mg injections: a single-center observational studySemantic proximity
Clinical Efficacy and Safety of Anti-vascular Biosimilars Compared to Reference Anti-vascular for neovascular age-related macular degeneration: A Systematic Review, Meta-Analysis and Meta-regression.Semantic proximity
Bevacizumab treatment for neovascular age-related macular degeneration in the setting of a clinic: "real life" long-term outcome.Semantic proximity
A New Generation of Gene Therapies as the Future of Wet AMD TreatmentSemantic proximity
Incidence of retinal pigment epithelium tears after intravitreal injection of Bevacizumab for the treatment of exudative age-related macular degenerationSemantic proximity
Select a neighboring publication to make it the new centre.